This is an oral medication in capsule form.
Zeposia® is a sphingosine 1-phosphate receptor modulator, which is thought to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.
Zeposia was approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Read the Society's news bulletin on the FDA approval of Zeposia here
to read the Zeposia Prescribing Information for healthcare professionals.
to read the Zeposia Medication Guide for patients.
SupportZEPOSIA 360 SUPPORT™
Financial Assistance Program
ZEPOSIA 360 SUPPORT™